Form 4: Enliven Therapeutics Insider Trades Common Stock

Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics, Inc., reported transactions involving the acquisition and disposition of company common stock and stock options on May 18, 2026, executed under a Rule 10b5-1 trading plan.

Summary

• Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics, Inc., engaged in several transactions on May 18, 2026.
• These transactions included the exercise of a stock option to acquire 5,000 shares of common stock at $2.48 per share.
• Concurrently, Collins disposed of a total of 5,000 shares of common stock through multiple sales at weighted average prices ranging from $38.855 to $41.605.
• The sales involved 3,475 shares at an average price of $39.534, 1,302 shares at an average price of $40.2473, and 223 shares at an average price of $41.2052.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on October 19, 2025, which is intended to satisfy affirmative defense conditions.
• Following these transactions, Collins beneficially owns 25,000 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. The transactions are routine disclosures under a pre-established Rule 10b5-1 plan, indicating planned equity management rather than a reaction to company performance.

Positives

• The exercise of stock options and subsequent sales were executed under a pre-established Rule 10b5-1 trading plan, indicating a structured and pre-determined approach to managing equity.
• The weighted average sale prices for the common stock were significantly higher than the exercise price of the stock options, suggesting profitable transactions for the reporting person.

Negatives

• The disposition of 5,000 shares of common stock by a key executive could be perceived negatively by the market, although it was part of a pre-planned strategy.
• The filing details multiple sales at varying prices, which, while common in Rule 10b5-1 plans, can sometimes create complexity in interpreting the overall financial impact for the executive.

Risks

• While the transactions were made under a Rule 10b5-1 plan, significant stock sales by a Chief Medical Officer could be interpreted as a lack of confidence in future stock performance, potentially impacting investor sentiment.
• The filing does not provide specific details on the reasons for adopting the Rule 10b5-1 plan, which could leave room for speculation regarding the executive's personal financial needs or strategic outlook.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from the company. It solely reports on past transactions by an insider.

Management Comments

• The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
• The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price for transactions executed in multiple trades.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those under Rule 10b5-1 plans, are common in the biotechnology and pharmaceutical sectors as executives manage their compensation and personal portfolios. The execution of these trades by Enliven Therapeutics' Chief Medical Officer is a routine disclosure under SEC regulations.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even under a pre-planned strategy, may lead to short-term market perception shifts. However, the Rule 10b5-1 plan mitigates concerns about insider trading based on non-public information.
• Employees: The transactions do not directly impact employees but reflect the executive compensation structure and equity management practices within the company.
• Creditors: No direct impact on creditors is indicated by these transactions.

Next Steps

• Continued adherence to the Rule 10b5-1 trading plan for any future transactions by Helen Louise Collins.
• Potential requests for detailed sales price information from the SEC, the Issuer, or security holders.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Options, Common Stock, Rule 10b5-1, Enliven Therapeutics, ELVN, Helen Louise Collins, Chief Medical Officer, Beneficial Ownership, Equity Transaction